The success of mRNA technology in Covid-19 vaccines has led to an 800% increase in licensing deal values for mRNA-based pharmaceuticals. Major companies are heavily investing in mRNA technology, but recent lawsuits by GSK against Pfizer, BioNTech, and Moderna have raised concerns.